43
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Early prediction of blonanserin response in Japanese patients with schizophrenia

, , &
Pages 1861-1866 | Published online: 23 Sep 2014

References

  • TenjinTMiyamotoSNinomiyaYProfile of blonanserin for the treatment of schizophreniaNeuropsychiatr Dis Treat2013958759423766647
  • MiyamotoSDuncanGEMarxCELiebermanJATreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMol Psychiatry20051017910415289815
  • KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
  • KishiTMatsudaYNakamuraHIwataNBlonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trialsJ Psychiatr Res201347214915423131856
  • KishiTMatsudaYIwataNCardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trialsPLoS One201492e8804924505373
  • ParkJIChoDHHahnSWThe advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosisInt Clin Psychopharmacol2014292778523970176
  • ChatterjeeAChakosMKoreenAPrevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patientsAm J Psychiatry199515212172417298526237
  • CorrellCUManuPOlshanskiyVNapolitanoBKaneJMMalhotraAKCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescentsJAMA2009302161765177319861668
  • LiuCCChienYLHsiehMHHwangTJHwuHGLiuCMAripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label studyJ Clin Psychopharmacol2013331182323277261
  • GaebelWRiesbeckMWölwerWMaintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on SchizophreniaJ Clin Psychiatry200768111763177418052570
  • KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
  • CorrellCUMalhotraAKKaushikSMcMenimanMKaneJMEarly prediction of antipsychotic response in schizophreniaAm J Psychiatry2003160112063206514594760
  • LeuchtSBuschRKisslingWKaneJMEarly prediction of antipsychotic nonresponse among patients with schizophreniaJ Clin Psychiatry200768335236017388703
  • LeuchtSZhaoJEarly improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development programJ Psychopharmacol201428438739424429222
  • LeuchtSShamsiSABuschRKisslingWKaneJMPredicting antipsychotic drug response – replication and extension to six weeks in an international olanzapine studySchizophr Res20081011–331231918308513
  • MiuraSClinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with riperidoneJpn J Clin Psychopharmacol200811297314
  • MurasakiMClinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidolJpn J Clin Psychopharmacol20071020592079
  • GarciaERobertMPerisFNakamuraHSatoNTerazawaYThe efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre studyCNS Drugs200923761562519552488
  • YangJBahkWMChoHSEfficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trialClin Neuropharmacol201033416917520661022
  • MallinckrodtCHKaiserCJWatkinJGMolenberghsGCarrollRJThe effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVAClin Trials20041647748916279288